Hikma expects its generics business to hit the top end of its guidance for 2021, after recent launches and an improved product mix drove up its sales and operating margin. Meanwhile, the firm has announced a licensing agreement with Almirall for its Finjuve finasteride brand as the latest in a series of deals.
Hikma expects its generics busines to hit the top end of guidance for 2021, with a forecast of a core operating margin that will be “closer to the top end of our guidance range of 22% to 24%, reflecting a more favorable product mix,” as generics sales are expect to land within the previously-announced range of $810m-$830m.
Reiterating its full-year guidance in a trading update – after a few months ago raising its expectations for 2021, having...
Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
